

## Pubblicazioni triennio 2016-2019

### Anno 2019

Abate, RE; Pasquale, R; Sacco, A; Piccirillo, MC; Morabito, A; Bidoli, P; Finocchiaro, G; Chiari, R; Foltran, L; Buosi, R; Tiseo, M; Giannetta, L; Battiloro, C; Fasola, G; Romano, G; Ciuffreda, L; Frassoldati, A; de Marinis, F; Cappuzzo, F; Normanno, N (2019) *Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib* *CANCERS* 11(10): - **IF<sub>2019</sub>=6,126** [Article]

Abbate, MI; Cortinovis, DL; Tiseo, M; Vavala, T; Cerea, G; Toschi, L; Canova, S; Colonese, F; Bidoli, P (2019) *Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review* *FUTURE ONCOLOGY* 15(9): 989-994 **IF<sub>2019</sub>=2,660** [Review]

Balsano, R; Tommasi, C; Garajova, I (2019) *State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now?* *ANTICANCER RESEARCH* 39(7): 3405-3412 **IF<sub>2019</sub>=1,994** [Proceedings Paper]

Barni, S; Livraghi, L; Gravina, A; ...; Musolino, A; Boggiani, D; ...; Riccardi, F; Mocerino, C; Febbraro, A (2019) *Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study* *JOURNAL OF GERIATRIC ONCOLOGY* 10(6): 990-993 **IF<sub>2019</sub>=2,761** [Letter]

Berardi, R; Mastroianni, C; Lo Russo, G; ...; Tiseo, M; ...; Bordi, P; ...; Morabito, A; Vincenzi, B; Arvat, E (2019) *Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study* *THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY* 11(): - **IF<sub>2019</sub>=6,852** [Article]

Bersanelli, M; Buti, S; De Giorgi, U; Di Maio, M; Giannarelli, D; Pignata, S; Banna, GL (2019) *State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough* *CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY* 139(): 87-90 **IF<sub>2019</sub>=5,833** [Review]

Bersanelli, M; Buti, S; Santoni, M; Ziglioli, F; Maestroni, U (2019) *Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions* *ANNALS OF TRANSLATIONAL MEDICINE* 7(): - **IF<sub>2019</sub>=3,297** [Editorial Material]

Bersanelli, M; Cortellini, A; Buti, S (2019) *The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a "transcriptomic compass"?* *ANNALS OF TRANSLATIONAL MEDICINE* 7(): - **IF<sub>2019</sub>=3,297** [Editorial Material]

Bersanelli, M; Gnetti, L; Varotti, E; Ampollini, L; Carbognani, P; Leonardi, F; Rusca, M; Campanini, N; Ziglioli, F; Dadomo, CI; Pilato, FP; Cortellini, A; Rapacchi, E; Caruso, G; Silini, EM; Maestroni, U; Buti, S (2019) *Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma* *IMMUNOTHERAPY* 11(1): 21-34 **IF<sub>2019</sub>=2,964** [Article]

Bersanelli, M; Santoni, M; Ticinesi, A; Buti, S (2019) *The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes* *TARGETED ONCOLOGY* 14(3): 247-252 **IF<sub>2019</sub>=4,036** [Article]

Bordi, P; Del Re, M; Minari, R; Rofi, E; Buti, S; Restante, G; Squadrilli, A; Crucitta, S; Casartelli, C; Gnetti, L; Azzoni, C; Bottarelli, L; Petrini, I; Cosenza, A; Ferri, L; Rapacchi, E; Danesi, R; Tiseo, M (2019) *From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients*

*treated with osimertinib for advanced T790M-positive NSCLC* LUNG CANCER 131(): 78-85 **IF<sub>2019</sub>=4,702** [Article]

Borghesi, A; Corazza, M; Chiaranda, G; Michiara, M; Mangone, L; Caruso, B; Falcini, F; Maestri, I; Ferretti, S (2019) *Second primary malignancies in patients with non-melanoma skin cancer: Results from a cancer registry-based study in Emilia Romagna, north-east Italy* CANCER EPIDEMIOLOGY 61(): 176-184 **IF<sub>2019</sub>=2,179** [Article]

Botta, L; Dal Maso, L; Guzzinati, S; Panato, C; Gatta, G; Trama, A; Rugge, M; Tagliabue, G; Casella, C; Caruso, B; Michiara, M; Ferretti, S; Sensi, F; Tumino, R; Toffolutti, F; Russo, AG; Caiazzo, AL; Mangone, L; Mazzucco, W; Iacovacci, S; Ricci, P; Gola, G; Candela, G; Sardo, AS; De Angelis, R; Buzzoni, C; Capocaccia, R; Crocetti, E; Falcini, F; Bianconi, F; Sciacca, S; Mazzoleni, G; Fusco, M; Rosso, S; Tisano, F; Fanetti, AC; Usala, M (2019) *Changes in life expectancy for cancer patients over time since diagnosis* JOURNAL OF ADVANCED RESEARCH 20(): 153-159 **IF<sub>2019</sub>=6,992** [Article]

Bruni, A; Giaj-Levra, N; Ciammella, P; Maragna, V; Ferrari, K; Bonti, V; Grossi, F; Greco, S; Graco, C; Borghetti, P; Franceschini, D; Capelletto, E; Perna, M; Banna, G; Vagge, S; Baldini, E; Bria, E; Botti, A; Tiseo, M; Paci, M; Taraborrelli, M; Poletti, V; Granone, P; Ricardi, U; Novello, S; Scotti, V (2019) *Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach* PLOS ONE 14(11): - **IF<sub>2019</sub>=2,740** [Article]

Bucchi, L; Baldacchini, F; Mancini, S; ...; Michiara, M; ...; Canuti, D; Desiderio, F; Monticelli, G (2019) *Estimating the impact of an organised screening programme on cervical cancer incidence: A 26-year study from northern Italy* INTERNATIONAL JOURNAL OF CANCER 144(5): 1017-1026 **IF<sub>2019</sub>=5,145** [Article]

Buti, S (2019) *A new prognostic model for localized renal cell carcinoma* WORLD JOURNAL OF UROLOGY 37(1): 211-212 **IF<sub>2019</sub>=3,217** [Letter]

Buti, S; Karakiewicz, PI; Bersanelli, M; Capitanio, U; Tian, Z; Cortellini, A; Taguchi, S; Briganti, A; Montorsi, F; Leonardi, F; Bandini, M (2019) *Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients* SCIENTIFIC REPORTS 9(): - **IF<sub>2019</sub>=3,998** [Article]

Buti, S; Leonetti, A; Lattanzi, E; D'Abbiero, N; Bersanelli, M (2019) *Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches"* ANNALS OF TRANSLATIONAL MEDICINE 7(): - **IF<sub>2019</sub>=3,297** [Editorial Material]

Capelletto, E; Migliorino, MR; Morabito, A; Chiari, R; Grossi, F; Tiseo, M; Di Costanzo, F; Delmonte, A; Romano, G; Galetta, D; Scotti, V; Gregorc, V; Pisconti, S; Ceresoli, GL; Del Conte, A; Ciuffreda, L; Colantonio, I; Bria, E; Ricciardi, S; Manzo, A; Metro, G; Morelli, AM; Critelli, R; Pacchiana, MV; Stura, I; Migliaretti, G; Novello, S (2019) *Final results of the SENECA (SEcond line NintEdanib in non-small cell lung Cancer) trial* LUNG CANCER 134(): 210-217 **IF<sub>2019</sub>=4,702** [Article]

Cazzaniga, ME; Pinotti, G; Montagna, E; ...; Musolino, A; ...; Pellegrino, B; ...; Tinari, N; Vandone, A; Vizzini, L (2019) *Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study* BREAST 48(): 7-16 **IF<sub>2019</sub>=3,754** [Article]

Cinausero, M; Laprovitera, N; De Maglio, G; Gerratana, L; Riefolo, M; Macerelli, M; Fiorentino, M; Porcellini, E; Buoro, V; Gelsomino, F; Squadrilli, A; Fasola, G; Negrini, M; Tiseo, M; Ferracin, M; Ardizzoni, A (2019) *KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in*

*metastatic nonsquamous NSCLC THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY* 11(): - **IF<sub>2019</sub>=6,852** [Article]

Cortellini, A; Bersanelli, M; Buti, S; ...; Tiseo, M; Michiara, M; ...; Ascierto, PA; Ficorella, C; Natoli, C (2019) *A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable* *JOURNAL FOR IMMUNOTHERAPY OF CANCER* 7(): - **IF<sub>2019</sub>=9,913** [Article]

Cortellini, A; Bersanelli, M; Ficorella, C; Buti, S (2019) *Family history of cancer and DNA damage response genes: Two sides of the same coin?* *THORACIC CANCER* 10(2): 401-401 **IF<sub>2019</sub>=2,610** [Letter]

Cortellini, A; Buti, S; Agostinelli, V; Bersanelli, M (2019) *A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients* *SEMINARS IN ONCOLOGY* 46(4-5): 362-371 **IF<sub>2019</sub>=4,213** [Review]

Cortellini, A; Buti, S; Santini, D; ...; Tiseo, M; Bersanelli, M; Michiara, M; ...; Fagnoli, MC; Ascierto, PA; Ficorella, C (2019) *Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study* *ONCOLOGIST* 24(6): E327-E337 **IF<sub>2019</sub>=5,025** [Article]

Cortellini, A; Chiari, R; Ricciuti, B; Metro, G; Perrone, F; Tiseo, M; Bersanelli, M; Bordi, P; Santini, D; Giusti, R; Grassadonia, A; Di Marino, P; Tinari, N; De Tursi, M; Zoratto, F; Veltri, E; Malorgio, F; Garufi, C; Russano, M; Anesi, C; Zeppola, T; Filetti, M; Marchetti, P; Berardi, R; Rinaldi, S; Tudini, M; Silva, RR; Pireddu, A; Atzori, F; Iacono, D; Migliorino, MR; Porzio, G; Cannita, K; Ficorella, C; Buti, S (2019) *Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients* *CLINICAL LUNG CANCER* 20(4): 237-+ **IF<sub>2019</sub>=3,550** [Article]

Cremolini, C; Rossini, D; Dell'Aquila, E; Lonardi, S; Conca, E; Del Re, M; Busico, A; Pietrantonio, F; Danesi, R; Aprile, G; Tamburini, E; Barone, C; Masi, G; Pantano, F; Pucci, F; Corsi, DC; Pella, N; Bergamo, F; Rofi, E; Barbara, C; Falcone, A; Santini, D (2019) *Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial* *JAMA ONCOLOGY* 5(3): 343-350 **IF<sub>2019</sub>=24,799** [Article]

Crinò, L; Bidoli, P; Delmonte, A; Grossi, F; De Marinis, F; Ardizzoni, A; Vitiello, F; Lo Russo, G; Parra, HS; Cortesi, E; Cappuzzo, F; Calabrò, L; Tiseo, M; Turci, D; Gamucci, T; Antonelli, P; Morabito, A; Chella, A; Giannarelli, D; Galetta, D (2019) *Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population* *ONCOLOGIST* 24(11): E1165-E1171 **IF<sub>2019</sub>=5,025** [Article]

Dal Maso, L; Panato, C; Guzzinati, S; ...; Michiara, M; ...; Gola, G; Candela, G; Sardo, AS (2019) *Prognosis and cure of long-term cancer survivors: A population-based estimation* *CANCER MEDICINE* 8(9): 4497-4507 **IF<sub>2019</sub>=3,491** [Article]

De Giorgi, U; Procopio, G; Giannarelli, D; Sabbatini, R; Bearz, A; Buti, S; Basso, U; Mitterer, M; Ortega, C; Bidoli, P; Ferrau, F; Crino, L; Frassoldati, A; Marchetti, P; Mini, E; Scoppola, A; Verusio, C; Fornarini, G; Carteni, G; Caserta, C; Sternberg, CN (2019) *Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab* *CLINICAL CANCER RESEARCH* 25(13): 3839-3846 **IF<sub>2019</sub>=10,107** [Article]

De Giorgi, U; Carteni, G; Giannarelli, D; ...; Buti, S; ...; Santoro, A; Francini, G; Aondio, G (2019) *Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme* BJU INTERNATIONAL 123(1): 98-105 **IF<sub>2019</sub>=4,806** [Article]

Dieci, MV; Bisagni, G; Brandes, AA; Frassoldati, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Rimanti, A; Beano, A; Zamagni, C; Parra, HS; Piacentini, F; Danese, S; Ferro, A; Cagossi, K; Sarti, S; Gambaro, AR; Romito, S; Bazan, V; Amaducci, L; Moretti, G; Foschini, MP; Balduzzi, S; Vicini, R; D'Amico, R; Griguolo, G; Guarneri, V; Conte, PF (2019) *Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial* BMC MEDICINE 17(1): - **IF<sub>2019</sub>=6,782** [Article]

Dieci, MV; Conte, P; Bisagni, G; Brandes, AA; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S; D'Amico, R; Guarneri, V (2019) *Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+breast cancer* ANNALS OF ONCOLOGY 30(3): 418-423 **IF<sub>2019</sub>=18,274** [Article]

Facchinetti, F; Gnetti, L; Balestra, V; Silva, M; Silini, EM; Ventura, L; Majori, M; Bordi, P; Tiseo, M (2019) *Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib* INVESTIGATIONAL NEW DRUGS 37(2): 360-363 **IF<sub>2019</sub>=3,525** [Article]

Facchinetti, F; Majori, M; Sabato, M; Gnetti, L; Tiseo, M (2019) *Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?* IMMUNOTHERAPY 11(3): 161-166 **IF<sub>2019</sub>=2,964** [Article]

Facchinetti, F; Tiseo, M (2019) *Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial* CHINESE CLINICAL ONCOLOGY 8(): - **IF<sub>2019</sub>=0,000** [Editorial Material]

Facchini, G; Rossetti, S; Berretta, M; ...; Gasparro, D; ...; Buonerba, C; Carteni, G; D'Aniello, C (2019) *Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results* JOURNAL OF TRANSLATIONAL MEDICINE 17(1): - **IF<sub>2019</sub>=4,124** [Article]

Farjadian, S; Bonatti, F; Soriano, A; Reina, M; Adorni, A; Graziano, C; Moghtaderi, M; Percesepe, A; Romeo, G; Martorana, D (2019) *A new MEFV gene mutation in an Iranian patient with familial Mediterranean fever* REUMATISMO 71(2): 85-87 **IF<sub>2019</sub>=0,000** [Article]

Franciosi, V; Maglietta, G; Degli Esposti, C; Caruso, G; Cavanna, L; Berte, R; Bacchini, G; Bocchi, L; Piva, E; Monfredo, M; Scafuri, V; Di Cesare, P; Melotti, B; Sequino, M; Rimanti, A; Binovi, C; Ghisoni, F; Caminiti, C (2019) *Early palliative care and quality of life of advanced cancer patients-a multicenter randomized clinical trial* ANNALS OF PALLIATIVE MEDICINE 8(4): 381-389 **IF<sub>2019</sub>=1,681** [Article]

Fumarola, C; Bozza, N; Castelli, R; Ferlenghi, F; Marseglia, G; Lodola, A; Bonelli, M; La Monica, S; Cretella, D; Alfieri, R; Minari, R; Galetti, M; Tiseo, M; Ardizzoni, A; Mor, M; Petronini, PG (2019) *Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines* FRONTIERS IN ONCOLOGY 9(): - **IF<sub>2019</sub>=4,848** [Article]

Gelsomino, F; Spallanzani, A; Garajova, I (2019) *The treatment of rectal cancer with synchronous liver metastases: A matter of strategy* CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 139(): 91-95 **IF<sub>2019</sub>=5,833** [Review]

Gianotti, E; Razzini, G; Bini, M; Crivellaro, C; Righi, A; Darcchio, S; Lui, S; Basirico, ML; Cocconi, S; Cagossi, K; Ferrari, A; Artioli, F (2019) *Scalp Cooling in Daily Clinical Practice for Breast Cancer Patients Undergoing Curative Chemotherapy: A Multicenter Interventional Study* ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING 6(3): 277-282 **IF<sub>2019</sub>=0,000** [Article]

Grossi, F; Genova, C; Crino, L; Delmonte, A; Turci, D; Signorelli, D; Passaro, A; Parra, HS; Catino, A; Landi, L; Gelsomino, F; Tiseo, M; Puppo, G; Roila, F; Ricciardi, S; Tonini, G; Cognetti, F; Toschi, L; Tassinari, D; Scoppola, A; Giannarelli, D; Cortesi, E (2019) *Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer* EUROPEAN JOURNAL OF CANCER 123(): 72-80 **IF<sub>2019</sub>=7,275** [Article]

Iacovelli, R; Galli, L; De Giorgi, U; Porta, C; Nole, F; Zucali, P; Sabbatini, R; Mosca, A; Atzori, F; Santini, D; Facchini, G; Fornarini, G; Buti, S; Massari, F; Masini, C; Ricotta, R; Biasco, E; Lolli, C; Gri, N; Verri, E; Miggiano, C; Vitale, MG; Tortora, G (2019) *The effect of a treatment delay on outcome in metastatic renal cell carcinoma* UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 37(8): - **IF<sub>2019</sub>=2,882** [Article]

La Monica, S; Minari, R; Cretella, D; Bonelli, M; Fumarola, C; Cavazzoni, A; Galetti, M; Digiaco, G; Riccardi, F; Petronini, PG; Tiseo, M; Alfieri, R (2019) *Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion* TARGETED ONCOLOGY 14(5): 619-626 **IF<sub>2019</sub>=4,036** [Article]

La Monica, S; Minari, R; Cretella, D; Flammini, L; Fumarola, C; Bonelli, M; Cavazzoni, A; Digiaco, G; Galetti, M; Madeddu, D; Falco, A; Lagrasta, CA; Squadrilli, A; Barocelli, E; Romanel, A; Quaini, F; Petronini, PG; Tiseo, M; Alfieri, R (2019) *Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC* JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 38(): - **IF<sub>2019</sub>=0,000** [Article]

Landi, L; Chiari, R; Tiseo, M; D'Inca, F; Dazzi, C; Chella, A; Delmonte, A; Bonanno, L; Giannarelli, D; Cortinovis, DL; de Marinis, F; Borra, G; Morabito, A; Gridelli, C; Galetta, D; Barbieri, F; Grossi, F; Capelletto, E; Minuti, G; Mazzoni, F; Verusio, C; Bria, E; Ali, G; Bruno, R; Proietti, A; Fontanini, G; Crino, L; Cappuzzo, F (2019) *Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial* CLINICAL CANCER RESEARCH 25(24): 7312-7319 **IF<sub>2019</sub>=10,107** [Article]

Landi, L; D'Inca, F; Gelibter, A; Chiari, R; Grossi, F; Delmonte, A; Passaro, A; Signorelli, D; Gelsomino, F; Galetta, D; Giannarelli, D; Parra, HS; Minuti, G; Tiseo, M; Migliorino, MR; Cognetti, F; Toschi, L; Bidoli, P; Piantedosi, F; Calabro, L; Cappuzzo, F (2019) *Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer* JOURNAL FOR IMMUNOTHERAPY OF CANCER 7(1): - **IF<sub>2019</sub>=9,913** [Article]

Leonetti, A; Assaraf, YG; Veltsista, PD; El Hassouni, B; Tiseo, M; Giovannetti, E (2019) *MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions* DRUG RESISTANCE UPDATES 42(): 1-11 **IF<sub>2019</sub>=11,000** [Review]

Leonetti, A; Boyd, L; Giuliani, J; Giovannetti, E; Garajova, I (2019) *Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on 'preclinical and early-phase clinical pharmacology'* EXPERT REVIEW OF CLINICAL PHARMACOLOGY 12(11): 1033-1036 **IF<sub>2019</sub>=3,481** [Review]

Leonetti, A; Facchinetti, F; Minari, R; Cortellini, A; Rolfo, CD; Giovannetti, E; Tiseo, M (2019) *Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges* CELLULAR ONCOLOGY 42(3): 261-273 **IF<sub>2019</sub>=5,304** [Review]

Leonetti, A; Sharma, S; Minari, R; Perego, P; Giovannetti, E; Tiseo, M (2019) *Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer* BRITISH JOURNAL OF CANCER 121(9): 725-737 **IF<sub>2019</sub>=5,791** [Review]

Leonetti, A; Wever, B; Mazzaschi, G; Assaraf, YG; Rolfo, C; Quaini, F; Tiseo, M; Giovannetti, E (2019) *Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer* DRUG RESISTANCE UPDATES 46(): - **IF<sub>2019</sub>=11,000** [Review]

Lonardi, S; Nasti, G; Fagnani, D; ... Negri, F; ...; Verusio, C; Zagonel, V; Zaniboni, A (2019) *Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study* TUMORI J 105(3): 243-252 **IF<sub>2019</sub>=1,707** [Article]

Loupakis, F; Intini, R; Cremolini, C; ...; Negri, F; ...; Zagonel, V; Fassan, M; Di Maio, M (2019) *A validated prognostic classifier for (V600E) BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study* EUROPEAN JOURNAL OF CANCER 118(): 121-130 **IF<sub>2019</sub>=7,275** [Article]

Lyons, PA; Peters, JE; Alberici, F; ...; Bonatti, F; ...; Martorana, D; ...; Holle, JU; Wallace, C; Smith, KGC (2019) *Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status* NATURE COMMUNICATIONS 10(): - **IF<sub>2019</sub>=12,121** [Article]

Masini, C; Vitale, MG; Maruzzo, M; Procopio, G; de Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Atzori, F; Cosmai, L; Vignani, F; Prati, G; Scagliarini, S; Guida, A; Berselli, A; Pinto, C (2019) *Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study* CLINICAL GENITOURINARY CANCER 17(1): E150-E155 **IF<sub>2019</sub>=2,695** [Article]

Mazzaschi, G; Facchinetti, F; Missale, G; Canetti, D; Madeddu, D; Zecca, A; Veneziani, M; Gelsomino, F; Goldoni, M; Buti, S; Bordi, P; Aversa, F; Ardizzoni, A; Quaini, F; Tiseo, M (2019) *The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC* LUNG CANCER 127(): 153-163 **IF<sub>2019</sub>=4,702** [Article]

Meijer, LL; Puik, JR; Le Large, TYS; Heger, M; Dijk, F; Funel, N; Wurdinger, T; Garajova, I; van Grieken, NCT; van de Wiel, MA; Giovannetti, E; Kazemier, G (2019) *Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors* CANCERS 11(8): - **IF<sub>2019</sub>=6,126** [Article]

Militello, AM; Zielli, T; Boggiani, D; Michiara, M; Naldi, N; Bortesi, B; Zanelli, P; Uliana, V; Giuliotti, S; Musolino, A (2019) *Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review* FRONTIERS IN ONCOLOGY 9(): - **IF<sub>2019</sub>=4,848** [Review]

Montagna, G; Anderson, D; Bochenek-Cibor, J; Bozovic-Spasojevic, I; Campos, C; Cavallero, S; Durutovic, I; Cuadra, MOG; Irfan, T; Joly, L; Kassem, L; Kolben, TM; Machacek, M; Khan, BM; Nagvekar, M; Pellegrino, B; Pogoda, K; Camara, GR; Ferreira, PS; Seferi, M; Talibova, N; Van den Rul, N; Vettus, E; Rocco, N (2019) *How to become a breast cancer specialist in 2018: The point of view of the second cohort of the Certificate of Competence in Breast Cancer (CCB2)* BREAST 43(): 18-21 **IF<sub>2019</sub>=3,754** [Article]

Negri, F; Bozzetti, C; Pedrazzi, G; Azzoni, C; Bottarelli, L; Squadrilli, A; Lagrasta, C; Tamagnini, I; Bisagni, A; Ragazzi, M; Porzio, R; Tomasello, G; Mori, D; Leonardi, F; Gnetti, L; Crafa, P; Sala, R; Cascinu, S (2019) *High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer* ONCOLOGY REPORTS 42(6): 2750-2758 **IF<sub>2019</sub>=3,417** [Article]

Negri, F; De Giorgi, A; Gilli, A; Azzoni, C; Bottarelli, L; Gnetti, L; Goldoni, M; Manotti, L; Sgargi, P; Michiara, M; Leonardi, F; Rindi, G; Cascinu, S; Silini, EM (2019) *Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series* SCIENTIFIC REPORTS 9(): - **IF<sub>2019</sub>=3,998** [Article]

Nicolai, N; Biondi, D; Catanzaro, MA; ...; Michiara, M; ...; Primic-Zakelj, M; Kunkler, I; Benhamou, E (2019) *Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference* EJSO 45(1): 60-66 **IF<sub>2019</sub>=3,959** [Article]

Orlandi, E; Alfieri, S; Simon, C; ...; Michiara, M; ...; Primic-Zakelj, M; Kunkler, I; Benhamou, E (2019) *Treatment challenges in and outside a network setting: Head and neck cancers* EJSO 45(1): 40-45 **IF<sub>2019</sub>=3,959** [Article]

Parisi, A; Cortellini, A; Cannita, K; Bersanelli, M; Ficorella, C (2019) *Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis* CASE REPORTS IN ONCOLOGICAL MEDICINE (): - **IF<sub>2019</sub>=0,000** [Article]

Parsons, MT; Tudini, E; Li, H; ...; Bortesi, B; ...; Naldi, N; ...; Schmutzler, RK; Goldgar, DE; Spurdle, AB (2019) *Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification* HUMAN MUTATION 40(9): 1557-1578 **IF<sub>2019</sub>=4,124** [Article]

Passaro, A; Prelaj, A; Bonanno, L; Tiseo, M; Tuzi, A; Proto, C; Chiari, R; Rocco, D; Genova, C; Sini, C; Cortinovis, D; Pilotto, S; Landi, L; Bennati, C; Camerini, A; Toschi, L; Putzu, C; Cerea, G; Spitaleri, G; Cappuzzo, F; de Marinis, F (2019) *Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations* CLINICAL LUNG CANCER 20(2): E186-E194 **IF<sub>2019</sub>=3,550** [Article]

Pellegrino, B; Mateo, J; Serra, V; Balmana, J (2019) *Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?* ESMO OPEN 4(2): - **IF<sub>2019</sub>=5,329** [Editorial Material]

Peters, S; Stahel, R; Bubendorf, L; Bonomi, P; Villegas, A; Kowalski, DM; Baik, CS; Isla, D; Carpeno, JD; Garrido, P; Rittmeyer, A; Tiseo, M; Meyenberg, C; de Haas, S; Lam, LH; Lu, MW; Stinchcombe, TE (2019) *Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers* CLINICAL CANCER RESEARCH 25(1): 64-72 **IF<sub>2019</sub>=10,107** [Article]

Peverelli, G; Raimondi, A; Ratta, R; Verzoni, E; Bregni, M; Cortesi, E; Carteni, G; Fornarini, G; Facchini, G; Buti, S; Galli, L; Tucci, M; Prisciandaro, M; Procopio, G (2019) *Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population* CLINICAL GENITOURINARY CANCER 17(4): 291-298 **IF<sub>2019</sub>=2,695** [Article]

Planchard, D; Boyer, MJ; Lee, JS; Dechaphunkul, A; Cheema, PK; Takahashi, T; Gray, JE; Tiseo, M; Ramalingam, SS; Todd, A; McKeown, A; Rukazenzov, Y; Ohe, Y (2019) *Postprogression Outcomes for*

*Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer* CLINICAL CANCER RESEARCH 25(7): 2058-2063 **IF<sub>2019</sub>=10,107** [Article]

Porta, C; Broglia, C; Negri, F (2019) *Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right Patient* HEPATOLOGY 70(1): 429-430 **IF<sub>2019</sub>=14,679** [Editorial Material]

Ravanelli, M; Agazzi, GM; Milanese, G; Roca, E; Silva, M; Tiseo, M; Rondi, P; Baggi, A; Ganeshan, B; Muri, M; Panni, S; Botti, C; Sverzellati, N; Maroldi, R; Berruti, A; Farina, D (2019) *Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: A multicentre retrospective study* EUROPEAN JOURNAL OF RADIOLOGY 118(): 251-256 **IF<sub>2019</sub>=2,687** [Article]

Rebuzzi, SE; Leonetti, A; Tiseo, M; Facchinetti, F (2019) *Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer* IMMUNOTHERAPY 11(12): 993-1003 **IF<sub>2019</sub>=2,964** [Editorial Material]

Reginelli, A; Capasso, R; Petrillo, M; Rossi, C; Faella, P; Grassi, R; Belfiore, MP; Rossi, G; Muto, M; Muto, P; Fiorello, A; Serra, N; Nizzoli, R; De Filippo, M; Cappabianca, S; Carrafiello, G; Brunese, L; Rotondo, A (2019) *Looking for Lepidic Component inside Invasive Adenocarcinomas Appearing as CT Solid Solitary Pulmonary Nodules (SPNs): CT Morpho-Densitometric Features and 18-FDG PET Findings* BIOMED RESEARCH INTERNATIONAL 2019(): - **IF<sub>2019</sub>=2,276** [Article]

Rihawi, K; Giannarelli, D; Galetta, D; Delmonte, A; Giavarra, M; Turci, D; Garassino, M; Tiseo, M (2019) *BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience* JOURNAL OF THORACIC ONCOLOGY 14(3): E57-E59 **IF<sub>2019</sub>=13,357** [Letter]

Russo, U; Sabatino, V; Nizzoli, R; Tiseo, M; Cappabianca, S; Reginelli, A; Carrafiello, G; Brunese, L; De Filippo, M (2019) *Transthoracic computed tomography-guided lung biopsy in the new era of personalized medicine* FUTURE ONCOLOGY 15(10): 1125-1134 **IF<sub>2019</sub>=2,660** [Article]

Santoni, M; Conti, A; Massari, F; Di Nunno, V; Faloppi, L; Galizia, E; Morbiducci, J; Piva, F; Buti, S; Iacovelli, R; Ferretti, B; Cimadamore, A; Scarpelli, M; Lopez-Beltran, A; Cheng, L; Battelli, N; Montironi, R (2019) *Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies* EXPERT REVIEW OF CARDIOVASCULAR THERAPY 17(12): 917-927 **IF<sub>2019</sub>=0,000** [Article]

Signorelli, D; Giannatempo, P; Grazia, G; Aiello, MM; Bertolini, F; Mirabile, A; Buti, S; Vasile, E; Scotti, V; Pisapia, P; Cona, MS; Rolfo, C; Malapelle, U; Costanzo, R; Bersanelli, M; Bonomo, P; Iacovelli, R; Pressiani, T; Raggi, D; Santoni, M (2019) *Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naive Vision of a Single Biomarker* BIOMED RESEARCH INTERNATIONAL 2019(): - **IF<sub>2019</sub>=2,276** [Review]

Trama, A; Botta, L; Foschi, R; ...; Michiara, M; ...; Hindi, N; Imbimbo, M; Capocaccia, R (2019) *Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet* FRONTIERS IN ONCOLOGY 9(): - **IF<sub>2019</sub>=4,848** [Article]

Trapani, S; Manicone, M; Sikokis, A; D'Abbio, N; Salaroli, F; Ceccon, G; Buti, S (2019) *Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a*

systematic review CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 142(): 9-15 **IF<sub>2019</sub>=5,833**  
[Review]

Van Den Borg, R; Leonetti, A; Tiseo, M; Giovannetti, E; Peters, GJ (2019) *Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine* EXPERT REVIEW OF ANTICANCER THERAPY 19(6): 461-471 **IF<sub>2019</sub>=3,573** [Review]

Van der Steen, N; Leonetti, A; Keller, K; Dekker, H; Funel, N; Lardon, F; Ruijtenbeek, R; Tiseo, M; Rolfo, C; Pauwels, P; Peters, GJ; Giovannetti, E (2019) *Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line* BIOCHEMICAL PHARMACOLOGY 166(): 128-138 **IF<sub>2019</sub>=4,960** [Article]

Van Der Steen, N; Zwaenepoel, K; Mazzaschi, G; Luirink, RA; Geerke, DP; de Beeck, KO; Hermans, C; Tiseo, M; Van Schil, P; Lardon, F; Germonpre, P; Rolfo, C; Giovannetti, E; Peters, GJ; Pauwels, P (2019) *The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies* MOLECULES 24(24): - **IF<sub>2019</sub>=3,267** [Article]

Vernieri, C; Galli, F; Ferrari, L; .....; Leonardi, F; ...; Dotti, KF; Galli, F; Di Bartolomeo, M (2019) *Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis* ONCOLOGIST 24(3): 385-393 **IF<sub>2019</sub>=5,025** [Article]

Verzoni, E; Carteni, G; Cortesi, E; ...; Buti, S; ...; Raimondi, A; De Giorgi, U; Procopio, G (2019) *Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program* JOURNAL FOR IMMUNOTHERAPY OF CANCER 7(): - **IF<sub>2019</sub>=9,913** [Article]

Vicentini, M; Zorzi, M; Bovo, E; ...; Michiara, M; ...; Palmonari, C; Casella, C; Puppo, A (2019) *Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study* INTERNATIONAL JOURNAL OF CANCER 145(1): 110-121 **IF<sub>2019</sub>=5,145** [Article]

## Anno 2018

Ampollini, L; Barocelli, E; Cavazzoni, A; Petronini, P; Mucchino, C; Cantoni, AM; Leonardi, F; Ventura, L; Barbieri, S; Colombo, P; Fusari, A; Carbognani, P; Rusca, M; Sonvico, F (2018) *Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model* JOURNAL OF THORACIC DISEASE 10():0-0 **IF<sub>2017</sub>=0** [Article]

Bersanelli, M; Brighenti, M; Buti, S; Barni, S; Petrelli, F (2018) *Patient performance status and cancer immunotherapy efficacy: a meta-analysis* MEDICAL ONCOLOGY 35(10):- **IF<sub>2017</sub>=2.92** [Review]

Bersanelli, M; Giannarelli, D; Castrignano, P; Fornarini, G; Panni, S; Mazzoni, F; Tiseo, M; Rossetti, S; Gambale, E; Rossi, E; Papa, A; Cortellini, A; Lolli, C; Ratta, R; Michiara, M; Milella, M; Luca, ED; Soraru, M; Mucciarini, C; Atzori, F; Banna, GL; Torre, LL; Vitale, MG; Massari, F; Rebutti, SE; Facchini, G; Schinzari, G; Tomao, S; Bui, S; Vaccaro, V; Procopio, G; Giorgi, UD; Santoni, M; Ficorella, C; Sabbatini, R; Maestri, A; Natoli, C; Tursi, MD; Maio, MD; Rapacchi, E; Pireddu, A; Sava, T; Lipari, H; Comito, F; Verzoni, E; Leonardi, F; Buti, S (2018) *INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study* IMMUNOTHERAPY 10(14):1229-1239 **IF<sub>2017</sub>=3.461** [Article]

Bersanelli, M; Gnetti, L; Azzoni, C; Bottarelli, L; Sverzellati, N; Campanini, N; Varotti, E; Corrado, M; Parziale, R; Rapacchi, E; Caruso, G; Leonardi, F; Silini, EM; Buti, S (2018) *Loss of heterozygosity of key*

*tumor suppressor genes in advanced renal cancer patients treated with nivolumab* IMMUNOTHERAPY 10(9):743-0 **IF<sub>2017</sub>=3.461** [Article]

Bersanelli, M; Leonardi, F; Buti, S (2018) *Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date* CANCER MANAGEMENT AND RESEARCH 10():3773-3780 **IF<sub>2017</sub>=3.702** [Review]

Bracarda, S; Galli, L; Maruzzo, M; Lo Re, G; Buti, S; Favaretto, A; Di Costanzo, F; Sacco, C; Merlano, M; Mucciarini, C; Zafarana, E; Romito, S; Maestri, A; Giorgio, CG; Ionta, MT; Turci, D; De Giorgi, U; Procopio, G; Cortesi, E; Giannarelli, D; Porta, C (2018) *Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program* FUTURE ONCOLOGY 14(14):1347-1354 **IF<sub>2017</sub>=2.369** [Article]

Brighenti, M; Tiseo, M (2018) *Is there still room for anti-angiogenic agents in small cell lung cancer?* TRANSLATIONAL CANCER RESEARCH 7():0-0 **IF<sub>2017</sub>=0** [Letter]

Callegari, D; Ranaghan, KE; Woods, CJ; Minari, R; Tiseo, M; Mor, M; Mulholland, AJ; Lodola, A (2018) *L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib* CHEMICAL SCIENCE 9(10):2740-2749 **IF<sub>2017</sub>=0** [Article]

Camidge, DR; Kim, DW; Tiseo, M; Langer, CJ; Ahn, MJ; Shaw, AT; Huber, RM; Hochmair, MJ; Lee, DH; Bazhenova, LA; Gold, KA; Ou, SHI; West, HL; Reichmann, W; Haney, J; Clackson, T; Kerstein, D; Gettinger, SN (2018) *Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials* JOURNAL OF CLINICAL ONCOLOGY 36(26):2693-0 **IF<sub>2017</sub>=26.303** [Article]

Camidge, DR; Kim, HR; Ahn, MJ; Yang, JCH; Han, JY; Lee, JS; Hochmair, MJ; Li, JYC; Chang, GC; Lee, KH; Gridelli, C; Delmonte, A; Campelo, RG; Kim, DW; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Califano, R; Ghosh, S; Spira, A; Gettinger, SN; Tiseo, M; Gupta, N; Haney, J; Kerstein, D; Popat, S (2018) *Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer* NEW ENGLAND JOURNAL OF MEDICINE 379(21):2027-2039 **IF<sub>2017</sub>=79.258** [Article]

Cervellin, G; Comelli, I; Rastelli, G; Sanchis-Gomar, F; Negri, F; De Luca, C; Lippi, G (2018) *Epidemiology and clinics of mushroom poisoning in Northern Italy: A 21-year retrospective analysis* HUMAN & EXPERIMENTAL TOXICOLOGY 37(7):697-703 **IF<sub>2017</sub>=1.84** [Article]

Conte, P; Frassoldati, A; Bisagni, G; Brandes, AA; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, EA; Vicini, R; Balduzzi, S; D'Amico, R; Guarneri, V; Giarratano, T; McMahon, L; De Salvo, GL; Dieci, MV; Maiorana, A; Ficarra, G; Caggia, F; Grisolia, D; Bartolini, S; Lorusso, V; Ardito, R; Tartarone, A; Vanella, P; Taverniti, C; Porpiglia, M; Spanu, PG; Biglia, N; Andreis, D; Piancastelli, A; Fedeli, A; Parra, HS; Gambaro, AR; Romito, S; Malossi, A; Gori, S; Miglietta, L; Del Mastro, L; Amoroso, D; Mansutti, M; Generali, D; Prati, G; Bertolini, A; Berardi, R; Zanni, A; Cottafavi, L; Bologna, A; Naso, G; Pancotti, A; Farci, D; Zoboli, A; Silva, R; Laudadio, L; Bordonaro, R; Marengo, D; Dongiovanni, V; Baldini, E; Saggia, C; Gorzegno, G; Cariello, A; Biganzoli, L; Rampello, E (2018) *Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study(aEuro<inverted exclamation>)* ANNALS OF ONCOLOGY 29(12):2328-2333 **IF<sub>2017</sub>=13.926** [Article]

Cortellini, A; Bersanelli, M; Buti, S; Gambale, E; Atzori, F; Zoratto, F; Parisi, A; Brocco, D; Pireddu, A; Cannita, K; Iacono, D; Migliorino, MR; Gamucci, T; De Tursi, M; Sidoni, T; Tiseo, M; Michiara, M; Papa,

A; Angius, G; Tomao, S; Fagnoli, MC; Natoli, C; Ficorella, C (2018) *Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study* IMMUNOTHERAPY 10(8):643-655 **IF<sub>2017</sub>=3.461** [Article]

Crisi, G; Filice, S; Michiara, M; Crafa, P; Lana, S (2018) *2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T* JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY 42(3):469-474 **IF<sub>2017</sub>=1.292** [Article]

Dal Maso, L; Panato, C; Franceschi, S; Serraino, D; Buzzoni, C; Busco, S; Ferretti, S; Torrisi, A; Falcini, F; Zorzi, M; Cirilli, C; Mazzucco, W; Magoni, M; Collarile, P; Pannoizzo, F; Caiazzo, AL; Russo, AG; Gili, A; Caldarella, A; Zanetti, R; Michiara, M; Mangone, L; Filiberti, RA; Fusco, M; Gasparini, F; Tagliabue, G; Cesaraccio, R; Tumino, R; Gatti, L; Tisano, F; Piffer, S; Sini, GM; Mazzoleni, G; Rosso, S; Fanetti, AC; Vaccarella, S (2018) *The impact of overdiagnosis on thyroid cancer epidemic in Italy, 1998-2012* EUROPEAN JOURNAL OF CANCER 94():6-15 **IF<sub>2017</sub>=7.191** [Article]

Del Re, M; Bordi, P; Rofi, E; Restante, G; Valleggi, S; Minari, R; Crucitta, S; Arrigoni, E; Chella, A; Morganti, R; Tiseo, M; Petrini, I; Danesi, R (2018) *The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response* BRITISH JOURNAL OF CANCER 119(10):1252-1258 **IF<sub>2017</sub>=5.922** [Article]

Facchinetti, F; Bordi, P; Bini, P; Bidin, L; Camisa, R; Tiseo, M (2018) *Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review* CURRENT DRUG TARGETS 19(14):1649-1656 **IF<sub>2017</sub>=3.112** [Review]

Facchinetti, F; Bordi, P; Leonetti, A; Buti, S; Tiseo, M (2018) *Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives* DRUG DESIGN DEVELOPMENT AND THERAPY 12():2857-2873 **IF<sub>2017</sub>=2.935** [Review]

Facchinetti, F; Bozzetti, F; Minari, R; Ceccon, G; Zielli, T; Florindo, I; Crisi, G; Tiseo, M (2018) *Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in EGFR-mutated non-small cell lung cancer* TUMORI J 104(6):0-0 **IF<sub>2017</sub>=1.304** [Editorial Material]

Facchinetti, F; Gnetti, L; Caruana, P; Fornaroli, F; de'Angelis, GL; Sabato, M; Ferri, L; Cosenza, A; Bordi, P; Tiseo, M (2018) *Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient* CLINICAL LUNG CANCER 19(5):0-0 **IF<sub>2017</sub>=4.204** [Article]

Facchinetti, F; Tiseo, M (2018) *No room for statins in the quest for survival benefits in small cell lung cancer* TRANSLATIONAL LUNG CANCER RESEARCH 7():0-0 **IF<sub>2017</sub>=0** [Editorial Material]

Facchinetti, F; Veneziani, M; Buti, S; Gelsomino, F; Squadrilli, A; Bordi, P; Bersanelli, M; Cosenza, A; Ferri, L; Rapacchi, E; Mazzaschi, G; Leonardi, F; Quaini, F; Ardizzoni, A; Missale, G; Tiseo, M (2018) *Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab* IMMUNOTHERAPY 10(8):681-694 **IF<sub>2017</sub>=3.461** [Article]

Franceschi, E; Tosoni, A; Minichillo, S; Depenni, R; Paccapelo, A; Bartolini, S; Michiara, M; Pavesi, G; Urbini, B; Crisi, G; Cavallo, MA; Tosatto, L; Dazzi, C; Biasini, C; Pasini, G; Balestrini, D; Zanelli, F; Ramponi, V; Fioravanti, A; Giombelli, E; De Biase, D; Baruzzi, A; Brandes, AA (2018) *The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power* WORLD NEUROSURGERY 112():0-0 **IF<sub>2017</sub>=0** [Article]

Gardini, AC; Faloppi, L; Aprile, G; Brunetti, O; Caparello, C; Corbelli, J; Chessa, L; Bruno, D; Ercolani, G; Leonetti, A; de Stefano, G; Farella, N; Foschi, FG; Lanzi, A; Dadduzio, V; Marisi, G; Masi, G; Negri, FV;

Pagan, F; Santini, D; Scarpi, E; Silletta, M; Silvestris, N; Tamburini, E; Tassinari, D; Vivaldi, C; Gentilucci, UV; Zagonel, V; Calvetti, L; Cascinu, S; Frassinetti, GL; Scartozzi, M (2018) *Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol* TUMORI J 104(6):476-479 **IF<sub>2017</sub>=1.304** [Article]

Gregorc, V; Gaafar, RM; Favaretto, A; Grossi, F; Jassem, J; Polychronis, A; Bidoli, P; Tiseo, M; Shah, R; Taylor, P; Novello, S; Muzio, A; Bearz, A; Greillier, L; Fontana, F; Salini, G; Lambiase, A; O'Brien, M (2018) *NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3* LANCET ONCOLOGY 19(6):799-811 **IF<sub>2017</sub>=36.418** [Article]

Guzzinat, S; Virdone, S; De Angelis, R; Panato, C; Buzzoni, C; Capocaccia, R; Francisci, S; Gigli, A; Zorzi, M; Tagliabue, G; Serraino, D; Falcini, F; Casella, C; Russo, AG; Stracci, F; Caruso, B; Michiara, M; Caiazzo, AL; Castaing, M; Ferretti, S; Mangone, L; Rudisi, G; Sensi, F; Mazzoleni, G; PannoZZo, F; Tumino, R; Fusco, M; Ricci, P; Gola, G; Giacomini, A; Tisano, F; Candela, G; Fanetti, AC; Pala, F; Sardo, AS; Rugge, M; Botta, L; Dal Mase, L (2018) *Characteristics of people living in Italy after a cancer diagnosis in 2010 and projections to 2020* BMC CANCER 18():- **IF<sub>2017</sub>=3.288** [Article]

Iacovelli, R; De Giorgi, U; Galli, L; Zucali, P; Nole, F; Sabbatini, R; Fraccon, AP; Basso, U; Mosca, A; Atzori, F; Santini, D; Facchini, G; Fornarini, G; Pasini, F; Masini, C; Massari, F; Buti, S; Sava, T; Sacco, C; Ricotta, R; Sperduti, I; Tortora, G; Porta, C (2018) *Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?* CLINICAL GENITOURINARY CANCER 16(5):355-0 **IF<sub>2017</sub>=2.539** [Article]

Iacovelli, R; Rocca, MC; Galli, L; Sabbatini, R; De Giorgi, U; Santini, D; Facchini, G; Mosca, A; Atzori, F; Zucali, P; Fornarini, G; Massari, F; Buti, S; Ricotta, R; Masini, C; Toscani, I; Biasco, E; Guida, A; Lolli, C; De Lisi, D; Rossetti, S; Terrone, C; Scartozzi, M; Miggiano, C; Pastorino, A; Bersanelli, M; Carlo-Stella, G; Pinto, C; Nobili, E; Nole, F; Tortora, G; Porta, C (2018) *The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma* ANTI-CANCER DRUGS 29(7):705-709 **IF<sub>2017</sub>=1.869** [Article]

Leonetti, A; D'Abbio, N; Baldari, G; Andreani, S; Ruffini, L; Viansone, AA; Buti, S (2018) *Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series* INTERNATIONAL JOURNAL OF UROLOGY 25(10):879-886 **IF<sub>2017</sub>=1.941** [Article]

Leonetti, A; Facchinetti, F; Rossi, G; Minari, R; Conti, A; Friboulet, L; Tiseo, M; Planchard, D (2018) *BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall* CANCER TREATMENT REVIEWS 66():82-94 **IF<sub>2017</sub>=8.122** [Review]

Leonetti, A; Facchinetti, F; Tiseo, M (2018) *Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?* ANNALS OF TRANSLATIONAL MEDICINE 6():- **IF<sub>2017</sub>=0** [Editorial Material]

Leonetti, A; Zielli, T; Buti, S (2018) *Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present)* FUTURE ONCOLOGY 14(22):2223-2224 **IF<sub>2017</sub>=2.369** [Letter]

Maines, F; De Giorgi, U; Procopio, G; Facchini, G; Fratino, L; Sabbatini, R; Gasparro, D; Basso, U; Mosillo, C; Campadelli, E; Massari, F; Sava, T; Sirotova, S; Messina, C; Scagliarini, S; Conteduca, V; Verzoni, E; Rossetti, S; Vecchia, A; Kinspergher, S; Caffo, O (2018) *Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program* FUTURE ONCOLOGY 14(26):2691-2700 **IF<sub>2017</sub>=2.369** [Article]

Mazzaschi, G; Madeddu, D; Falco, A; Bocchialini, G; Goldoni, M; Sogni, F; Armani, G; Lagrasta, CA; Lorusso, B; Mangiaracina, C; Vilella, R; Frati, C; Alfieri, R; Ampollini, L; Veneziani, M; Silini, EM; Ardizzoni, A; Urbanek, K; Aversa, F; Quaini, F; Tiseo, M (2018) *Low PD-1 Expression in Cytotoxic CD8(+) Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value* CLINICAL CANCER RESEARCH 24(2):407-419 **IF<sub>2017</sub>=10.199** [Article]

Mengoli, MC; Rossi, G; Cavazza, A; Franco, R; Marino, FZ; Migaldi, M; Gnetti, L; Silini, EM; Ampollini, L; Tiseo, M; Lococo, F; Fournel, L; Spagnolo, P; Cottin, V; Colby, TV (2018) *Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study* AMERICAN JOURNAL OF SURGICAL PATHOLOGY 42(5):646-655 **IF<sub>2017</sub>=5.878** [Article]

Minari, R; Bordi, P; Del Re, M; Facchinetti, F; Mazzoni, F; Barbieri, F; Camerini, A; Comin, CE; Gnetti, L; Azzoni, C; Nizzoli, R; Bortesi, B; Rofi, E; Petreni, P; Campanini, N; Rossi, G; Danesi, R; Tiseo, M (2018) *Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy* LUNG CANCER 115():21-27 **IF<sub>2017</sub>=4.486** [Article]

Minari, R; Bordi, P; La Monica, S; Squadrilli, A; Leonetti, A; Bottarelli, L; Azzoni, C; Lagrasta, CAM; Gnetti, L; Campanini, N; Petronini, PG; Alfieri, R; Tiseo, M (2018) *Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC* JOURNAL OF THORACIC ONCOLOGY 13(6):0-0 **IF<sub>2017</sub>=10.336** [Article]

Musolino, A; Falcini, F; Sikokis, A; Boggiani, D; Rimanti, A; Pellegrino, B; Silini, EM; Campanini, N; Barbieri, E; Zamagni, C; Esposti, RD; Cortesi, L; Bisagni, G; Cavanna, L; Frassoldati, A; Sgargi, P; Michiara, M (2018) *Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study* EUROPEAN JOURNAL OF CANCER 88():10-20 **IF<sub>2017</sub>=7.191** [Article]

Paolini, D; Tiseo, M; Demma, F; Furneri, G; Dionisi, M; Akkermans, M; Marchetti, A (2018) *Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non-Small-cell Lung Cancer: Clinical and Budget Effect* CLINICAL LUNG CANCER 19(5):0-0 **IF<sub>2017</sub>=4.204** [Article]

Pellegrino, B; Facchinetti, F; Bordi, P; Silva, M; Gnetti, L; Tiseo, M (2018) *Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature* CLINICAL LUNG CANCER 19(2):0-0 **IF<sub>2017</sub>=4.204** [Review]

Pilotto, S; Rossi, A; Vavala, T; Follador, A; Tiseo, M; Galetta, D; Morabito, A; Di Maio, M; Martelli, O; Caffo, O; Piovano, PL; Cortinovis, D; Zilembo, N; Casartelli, C; Banna, GL; Ardizzoia, A; Barzelloni, ML; Bearz, A; Genestreti, G; Mucciarini, C; Filipazzi, V; Menis, J; Rizzo, E; Barbieri, F; Rijavec, E; Cecere, F; Spitaleri, G; Bria, E; Novello, S (2018) *Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study* CLINICAL LUNG CANCER 19(1):93-0 **IF<sub>2017</sub>=4.204** [Article]

Procopio, G; Prisciandaro, M; Iacovelli, R; Cortesi, E; Fornarini, G; Facchini, G; Carteni, G; Sabbatini, R; Del Bene, G; Galli, L; Caserta, C; Multari, AG; Bregni, M; Massari, F; Buti, S; De Giorgi, U; Zustovich, F; Milella, M; Calabro, F; Mancini, ML; Tortora, G; Vernieri, C; Santini, D; Soraru, M; Ricotta, R; Masini, C; Tucci, M; Fedeli, SL; Ortega, C; Mecozzi, A; Ratta, R; Sternberg, CN; Verzoni, E (2018) *Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program* CLINICAL GENITOURINARY CANCER 16(4):0-0 **IF<sub>2017</sub>=2.539** [Article]

Rebuzzi, SE; Bregni, G; Grassi, M; Damiani, A; Buscaglia, M; Buti, S; Fornarini, G (2018) *Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature* IMMUNOTHERAPY 10(13):1123-1132 **IF<sub>2017</sub>=3.461** [Review]

Rimassa, L; Assenat, E; Peck-Radosavljevic, M; Pracht, M; Zagonel, V; Mathurin, P; Caremoli, ER; Porta, C; Daniele, B; Bolondi, L; Mazzaferro, V; Harris, W; Damjanov, N; Pastorelli, D; Reig, M; Knox, J; Negri, F; Trojan, J; Lopez, CL; Personeni, N; Decaens, T; Dupuy, M; Sieghart, W; Abbadessa, G; Schwartz, B; Lamar, M; Goldberg, T; Shuster, D; Santoro, A; Bruix, J (2018) *Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study* LANCET ONCOLOGY 19(5):682-693 **IF<sub>2017</sub>=36.418** [Article]

Santoni, M; Battelli, N; Buti, S (2018) *Durvalumab in Stage III Non-Small-Cell Lung Cancer* NEW ENGLAND JOURNAL OF MEDICINE 378(9):869-869 **IF<sub>2017</sub>=79.258** [Letter]

Santoni, M; Conti, A; Buti, S; Bersanelli, M; Foghini, L; Piva, F; Giulietti, M; Lusuardi, L; Battelli, N (2018) *Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis* IMMUNOTHERAPY 10(15):1303-1314 **IF<sub>2017</sub>=3.461** [Review]

Santoni, M; Piva, F; De Giorgi, U; Mosca, A; Bassos, U; Santini, D; Buti, S; Lolli, C; Terrone, C; Maruzzo, M; Iuliani, M; Bersanelli, M; Conti, A; Mazzucchelli, R; Montironi, R; Burattini, L; Berardi, R (2018) *Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma* ANTICANCER RESEARCH 38(10):5773-5782 **IF<sub>2017</sub>=1.865** [Article]

Tibaldi, C; Camerini, A; Tiseo, M; Mazzoni, F; Barbieri, F; Vittimberga, I; Brighenti, M; Boni, L; Baldini, E; Gilli, A; Honeywell, R; Chartoire, M; Peters, GJ; Giovannetti, E (2018) *Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study* BRITISH JOURNAL OF CANCER 119(11):1326-1331 **IF<sub>2017</sub>=5.922** [Article]

Tiseo, M; Boni, L; Ardizzoni, A (2018) *Is the door open to further investigation with antiangiogenesis in SCLC?* JOURNAL OF THORACIC DISEASE 10():0-0 **IF<sub>2017</sub>=0** [Letter]

Viansone, AA; Boggiani, D; Musolino, A (2018) *Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors* JAMA ONCOLOGY 4(1):132-132 **IF<sub>2017</sub>=0** [Letter]

Zucali, PA; De Pas, T; Palmieri, G; Favaretto, A; Chella, A; Tiseo, M; Caruso, M; Simonelli, M; Perrino, M; De Vincenzo, F; Toffalorio, F; Damiano, V; Pasello, G; Garbella, E; Ali, M; Conforti, F; Ottaviano, M; Cioffi, A; De Placido, S; Giordano, L; Bertossi, M; Destro, A; Di Tommaso, L; Santoro, A (2018) *Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy* JOURNAL OF CLINICAL ONCOLOGY 36(4):342-0 **IF<sub>2017</sub>=26.303** [Article]

## Anno 2017

Ampollini, L; Gnetti, L; Goldoni, M; Viani, L; Faedda, E; Campanini, N; Caruana, P; Crafa, P; Negri, F; Pucci, F; Leonardi, F; Ventura, L; Balestra, V; Braggio, C; Bocchialini, G; Del Rio, P; Silini, EM; Carbognani, P; Rusca, M (2017) *Pulmonary metastasectomy for colorectal cancer: analysis of prognostic factors affecting survival* JOURNAL OF THORACIC DISEASE 9():0-0 **IF<sub>2017</sub>=0** [Article]

Aprile, G; Negri, FV; Giuliani, F; De Carlo, E; Melisi, D; Simionato, F; Silvestris, N; Brunetti, O; Leone, F; Marino, D; Santini, D; Dell'Aquila, E; Zeppola, T; Puzzone, M; Scartozzi, M (2017) *Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?* CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 115():1-12 **IF<sub>2017</sub>=4.495** [Review]

- Basile, D; Garattini, SK; Bonotto, M; Ongaro, E; Casagrande, M; Cattaneo, M; Fanotto, V; De Carlo, E; Loupakis, F; Urbano, F; Negri, FV; Pella, N; Russano, M; Brunetti, O; Scartozzi, M; Santini, D; Silvestris, N; Gardini, AC; Puzzone, M; Calvetti, L; Cardarelli, N; Aprile, G (2017) *Immunotherapy for colorectal cancer: where are we heading?* EXPERT OPINION ON BIOLOGICAL THERAPY 17(6):709-721 **IF<sub>2017</sub>=3.974** [Review]
- Bersanelli, M; Bini, P; Rabaiotti, E; Facchinetti, F; De Filippo, M; Bortesi, B; Buti, S; Tiseo, M (2017) *Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder* TUMORI 103(1):66-71 **IF<sub>2017</sub>=1.304** [Article]
- Bersanelli, M; Buti, S (2017) *Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential* THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 9(10):627-636 **IF<sub>2017</sub>=6.238** [Review]
- Bersanelli, M; Gelsomino, F; Buti, S; Fiorentino, M; Tiseo, M (2017) *Plasma genotyping for EGFR T790M in non-small cell lung cancer: ready for clinical practice?* TRANSLATIONAL CANCER RESEARCH 6():0-0 **IF<sub>2017</sub>=0** [Editorial Material]
- Bersanelli, M; Leonetti, A; Buti, S (2017) *The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade* IMMUNOTHERAPY 9(14):1127-1131 **IF<sub>2017</sub>=3.461** [Editorial Material]
- Bersanelli, M; Leonetti, A; Buti, S; Michiara, M (2017) *Finding NEMO in NRAS-mutant melanoma: a step towards a sequential strategy?* LANCET ONCOLOGY 18(6):0-0 **IF<sub>2017</sub>=36.418** [Letter]
- Bonelli, MA; Digiaco, G; Fumarola, C; Alfieri, R; Quainia, F; Falco, A; Madeddu, D; La Monica, S; Cretella, D; Ravelli, A; Ulivi, P; Tebaldi, M; Calistri, D; Delmonte, A; Ampollini, L; Carbognani, P; Tiseo, M; Cavazzoni, A; Petronini, PG (2017) *Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells* NEOPLASIA 19(8):637-648 **IF<sub>2017</sub>=4.994** [Article]
- Bordi, P; Tiseo, M; Rofi, E; Petrini, I; Restante, G; Danesi, R; Del Re, M (2017) *Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment* CLINICAL LUNG CANCER 18(6):692-697 **IF<sub>2017</sub>=4.204** [Article]
- Buti, S; Bersanelli, M (2017) *Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?* JOURNAL OF CLINICAL ONCOLOGY 35(16):1858-0 **IF<sub>2017</sub>=26.303** [Letter]
- Buti, S; Bersanelli, M; Maines, F; Facchini, G; Gelsomino, F; Zustovich, F; Santoni, M; Verri, E; De Giorgi, U; Masini, C; Morelli, F; Vitale, MG; Sava, T; Prati, G; Librici, C; Fraccon, AP; Fornarini, G; Maruzzo, M; Leonardi, F; Caffo, O (2017) *First-Line Pazopanib in Non-clear-cell Renal carcinoma: The Italian Retrospective Multicenter PANORAMA Study* CLINICAL GENITOURINARY CANCER 15(4):0-0 **IF<sub>2017</sub>=2.539** [Article]
- Buti, S; Donini, M; Bersanelli, M; Gattara, A; Leonardi, F; Passalacqua, R (2017) *Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study* DRUGS IN R&D 17(4):585-596 **IF<sub>2017</sub>=0** [Article]
- Buti, S; Puligandla, M; Bersanelli, M; DiPaola, RS; Manola, J; Taguchi, S; Haas, NB (2017) *Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population* ANNALS OF ONCOLOGY 28(11):2747-2753 **IF<sub>2017</sub>=13.926** [Article]

Capasso, R; Nizzoli, R; Tiseo, M; Pedrazzi, G; Brunese, L; Rotondo, A; De Filippo, M (2017) *Extra-pleuric coaxial system for CT-guided percutaneous fine-needle aspiration biopsy (FNAB) of small (<= 20 mm) lung nodules: a novel technique using multiplanar reconstruction (MPR) images* MEDICAL ONCOLOGY 34(2):- **IF<sub>2017</sub>=2.92** [Article]

Cavazzoni, A; La Monica, S; Alfieri, R; Ravelli, A; Van Der Steen, N; Sciarrillo, R; Madeddu, D; Lagrasta, CAM; Quaini, F; Bonelli, M; Fumarola, C; Cretella, D; Digiaco, G; Tiseo, M; Peters, GJ; Ardizzoni, A; Petronini, PG; Giovannetti, E (2017) *Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN* ONCOTARGET 8(32):53068-53083 **IF<sub>2017</sub>=0** [Article]

Cazzaniga, ME; Airoldi, M; Arcangeli, V; Artale, S; Atzori, F; Ballerio, A; Bianchi, GV; Blasi, L; Campidoglio, S; Ciccarese, M; Cursano, MC; Piezzo, M; Fabi, A; Ferrari, L; Ferzi, A; Ficarella, C; Frassoldati, A; Fumagalli, A; Garrone, O; Gebbia, V; Generali, D; La Verde, N; Maur, M; Michelotti, A; Moretti, G; Musolino, A; Palumbo, R; Pistelli, M; Porpiglia, M; Sartori, D; Scavelli, C; Schirone, A; Turletti, A; Valerio, MR; Vici, P; Zambelli, A; Clivio, L; Torri, V (2017) *Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR plus ) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study* BREAST 35():115-121 **IF<sub>2017</sub>=2.951** [Article]

Del Re, M; Bordi, P; Petrini, I; Rofi, E; Mazzoni, F; Belluomini, L; Vasile, E; Restante, G; Di Costanzo, F; Falcone, A; Frassoldati, A; van Schaik, RHN; Steendam, CMJ; Chella, A; Tiseo, M; Morganti, R; Danesi, R (2017) *Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment* ONCOTARGET 8(49):86056-86065 **IF<sub>2017</sub>=0** [Article]

Del Re, M; Tiseo, M; Bordi, P; D'Incecco, A; Camerini, A; Petrini, I; Lucchesi, M; Inno, A; Spada, D; Vasile, E; Citi, V; Malpeli, G; Testa, E; Gori, S; Falcone, A; Amoroso, D; Chella, A; Cappuzzo, F; Ardizzoni, A; Scarpa, A; Danesi, R (2017) *Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA* ONCOTARGET 8(8):13611-13619 **IF<sub>2017</sub>=0** [Article]

Facchinetti, F; Rossi, G; Bria, E; Soria, JC; Besse, B; Minari, R; Friboulet, L; Tiseo, M (2017) *Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition* CANCER TREATMENT REVIEWS 55():83-95 **IF<sub>2017</sub>=8.122** [Review]

Facchinetti, F; Tiseo, M (2017) *Ceritinib in ROS1-positive non-small cell lung cancer patients: does clinical evidence carry clinical impact?* TRANSLATIONAL CANCER RESEARCH 6():0-0 **IF<sub>2017</sub>=0** [Editorial Material]

Ferolla, P; Brizzi, MP; Meyer, T; Mansoor, W; Mazieres, J; Do Cao, C; Lena, H; Berruti, A; Damiano, V; Buikhuisen, W; Gronbaek, H; Lombard-Bohas, C; Grohe, C; Minotti, V; Tiseo, M; De Castro, J; Reed, N; Gislimberti, G; Singh, N; Stankovic, M; Oberg, K; Baudin, E (2017) *Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial* LANCET ONCOLOGY 18(12):1652-1664 **IF<sub>2017</sub>=36.418** [Article]

Fumarola, C; Cretella, D; La Monica, S; Bonelli, MA; Alfieri, R; Caffarra, C; Quaini, F; Madeddu, D; Falco, A; Cavazzoni, A; Digiaco, G; Mazzaschi, G; Vivo, V; Barocelli, E; Tiseo, M; Petronini, PG; Ardizzoni, A (2017) *Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by*

*targeting downstream signaling involved in glucose metabolism* ONCOTARGET 8(54):91841-91859  
IF<sub>2017</sub>=0 [Article]

Garattini, SK; Basile, D; Cattaneo, M; Fanotto, V; Ongaro, E; Bonotto, M; Negri, FV; Berenato, R; Ermacora, P; Cardellino, GG; Giovannoni, M; Pella, N; Scartozzi, M; Antonuzzo, L; Silvestris, N; Fasola, G; Aprile, G (2017) *Molecular classifications of gastric cancers: Novel insights and possible future applications* WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY 9(5):194-208 IF<sub>2017</sub>=0 [Article]

Gelsomino, F; Leonetti, A; Rihawi, K; Sperandi, F; Casolari, L; Melotti, B; Fiorentino, M; Ardizzoni, A (2017) *Immune checkpoint inhibition in small cell lung cancer: a key to reach an unmet need?* TRANSLATIONAL CANCER RESEARCH 6():0-0 IF<sub>2017</sub>=0 [Editorial Material]

Gobbini, E; Galetta, D; Tiseo, M; Graziano, P; Rossi, A; Bria, E; Di Maio, M; Rossi, G; Gregorc, V; Riccardi, F; Scotti, V; Ceribelli, A; Buffoni, L; Delmonte, A; Franchina, T; Migliorino, MR; Cortinovia, D; Pisconti, S; Bordi, P; Catino, A; Maiello, E; Arizio, F; Novello, S (2017) *Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study* LUNG CANCER 111():30-37 IF<sub>2017</sub>=4.486 [Article]

Iacovelli, R; Rocca, MC; Galli, L; De Giorgi, U; Sabbatini, R; Santoni, M; Mosca, A; Fornarini, G; Massari, F; Masini, C; Bersanelli, M; Biasco, E; Lolli, C; Guida, A; Berardi, R; Terrone, C; Pastorino, A; Ardizzoni, A; Pinto, C; Buti, S; Nole, F; Tortora, G (2017) *Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer* UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 35(9):- IF<sub>2017</sub>=3.397 [Article]

Kim, DW; Tiseo, M; Ahn, MJ; Reckamp, KL; Hansen, KH; Kim, SW; Huber, RM; West, HL; Groen, HJM; Hochmair, MJ; Leighl, NB; Gettinger, SN; Langer, CJ; Rodriguez, LGPA; Smit, EF; Kim, ES; Reichmann, W; Haluska, FG; Kerstein, D; Camidge, DR (2017) *Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial* JOURNAL OF CLINICAL ONCOLOGY 35(22):2490-0 IF<sub>2017</sub>=26.303 [Article]

La Monica, S; Cretella, D; Bonelli, M; Fumarola, C; Cavazzoni, A; Digiacomo, G; Flammini, L; Barocelli, E; Minari, R; Naldi, N; Petronini, PG; Tiseo, M; Alfieri, R (2017) *Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines* JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 36():- IF<sub>2017</sub>=6.217 [Article]

Leonetti, A; Leonardi, F; Bersanelli, M; Buti, S (2017) *Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma* THERAPEUTICS AND CLINICAL RISK MANAGEMENT 13():799-806 IF<sub>2017</sub>=1.995 [Review]

Marina, M; Ceda, GP; Corcione, L; Sgargi, P; Michiara, M; Silini, EM; Ceresini, G (2017) *Size of thyroid carcinoma by histotype and variants: A population-based study in a mildly iodine-deficient area* HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 39(10):2095-2103 IF<sub>2017</sub>=2.471 [Article]

Mengoli, MC; Rossi, G; Tiseo, M; Barbieri, F; Pifferi, M; Bertolini, F; Lococo, F (2017) *'Turban-like' skull metastasis from pulmonary adenocarcinoma* THORAX 72(8):767-768 IF<sub>2017</sub>=9.655 [Article]

Mozzoni, P; Ampollini, L; Goldoni, M; Alinovi, R; Tiseo, M; Gnetti, L; Carbognani, P; Rusca, M; Mutti, A; Percesepe, A; Corradi, M (2017) *MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study* DISEASE MARKERS ():- IF<sub>2017</sub>=2.949 [Article]

Musolino, A; Campone, M; Neven, P; Denduluri, N; Barrios, CH; Cortes, J; Blackwell, K; Soliman, H; Kahan, Z; Bonnefoi, H; Squires, M; Zhang, Y; Deudon, S; Shi, MM; Andre, F (2017) *Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2(-) breast cancer that had progressed during or after prior endocrine therapy* BREAST CANCER RESEARCH 19():- **IF<sub>2017</sub>=6.142** [Article]

Negri, FV; De Giorgi, A; Bozzetti, C; Squadrilli, A; Petronini, PG; Leonardi, F; Bisogno, L; Garofano, L (2017) *Fingerprint Change: Not Visible, But Tangible* JOURNAL OF FORENSIC SCIENCES 62(5):1372-1373 **IF<sub>2017</sub>=1.184** [Article]

Pacchiana, MV; Capelletto, E; Carnio, S; Gridelli, C; Rossi, A; Galetta, D; Montagna, ES; Bordi, P; Ceribelli, A; Cortinovis, D; Scotti, V; Martelli, O; Valmadre, G; Del Conte, A; Miccianza, A; Morena, R; Rosetti, F; Di Maio, M; Ostacoli, L; Novello, S (2017) *Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey* CLINICAL LUNG CANCER 18(4):381-387 **IF<sub>2017</sub>=4.204** [Article]

Pellegrino, B; Musolino, A; Tiseo, M (2017) *Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient* ANNALS OF ONCOLOGY 28(6):1405-1406 **IF<sub>2017</sub>=13.926** [Letter]

Proto, C; Lo Russo, G; Corrao, G; Ganzinelli, M; Facchinetti, F; Minari, R; Tiseo, M; Garassino, MC (2017) *Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms* TUMORI JOURNAL 103(4):325-337 **IF<sub>2017</sub>=1.304** [Review]

Puliti, D; Bucchi, L; Mancini, S; Paci, E; Baracco, S; Campari, C; Canuti, D; Cirilli, C; Collina, N; Conti, GM; Di Felice, E; Falcini, F; Michiara, M; Negri, R; Ravaioli, A; de' Bianchi, PS; Serafini, M; Zorzi, M; Caldarella, A; Cataliotti, L; Zappa, M (2017) *Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy* EUROPEAN JOURNAL OF CANCER 75():109-116 **IF<sub>2017</sub>=7.191** [Article]

Rihawi, K; Gelsomino, F; Sperandi, F; Melotti, B; Fiorentino, M; Casolari, L; Ardizzoni, A (2017) *Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence* THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE 11(9):353-373 **IF<sub>2017</sub>=3.592** [Review]

Rossi, G; Jocolle, G; Conti, A; Tiseo, M; Marino, FZ; Donati, G; Franco, R; Bono, F; Barbisan, F; Facchinetti, F (2017) *Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives* LUNG CANCER-TARGETS AND THERAPY 8():45-55 **IF<sub>2017</sub>=0** [Review]

Rossi, G; Ragazzi, M; Tamagnini, I; Mengoli, MC; Vincenzi, G; Barbieri, F; Piccioli, S; Bisagni, A; Vavala, T; Righi, L; Novello, S; Gelsomino, F; Tiseo, M (2017) *Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?* CURRENT DRUG TARGETS 18(1):13-26 **IF<sub>2017</sub>=3.112** [Review]

Rugo, HS; Tredan, O; Ro, J; Morales, SM; Campone, M; Musolino, A; Afonso, N; Ferreira, M; Park, KH; Cortes, J; Tan, AR; Blum, JL; Eaton, L; Gause, CK; Wang, Z; Im, E; Mauro, DJ; Jones, MB; Denker, A; Baselga, J (2017) *A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer* BREAST CANCER RESEARCH AND TREATMENT 165(3):601-609 **IF<sub>2017</sub>=3.605** [Article]

Santini, D; Ratta, R; Pantano, F; De Lisi, D; Maruzzo, M; Galli, L; Biasco, E; Farnesi, A; Buti, S; Sternberg, CN; Cerbone, L; Di Lorenzo, G; Spoto, S; Sterpi, M; De Giorgi, U; Berardi, R; Torniai, M; Camerini, A; Massari, F; Procopio, G; Tonini, G (2017) *Outcome of oligoprogressing metastatic renal cell carcinoma*

*patients treated with locoregional therapy: a multicenter retrospective analysis* ONCOTARGET 8(59):100708-100716 **IF<sub>2017</sub>=0** [Article]

Taguchi, S; Buti, S; Fukuhara, H; Otsuka, M; Bersanelli, M; Morikawa, T; Miyazaki, H; Nakagawa, T; Fujimura, T; Kume, H; Igawa, Y; Homma, Y (2017) *Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?* PLOS ONE 12(2):- **IF<sub>2017</sub>=0** [Article]

Tiseo, M; Boni, L; Ambrosio, F; Camerini, A; Baldini, E; Cinieri, S; Brighenti, M; Zanelli, F; Defraia, E; Chiari, R; Dazzi, C; Tibaldi, C; Turolla, GM; D'Alessandro, V; Zilembo, N; Trolese, AR; Grossi, F; Riccardi, F; Ardizzoni, A (2017) *Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial* JOURNAL OF CLINICAL ONCOLOGY 35(12):1281-0 **IF<sub>2017</sub>=26.303** [Article]

Tiseo, M; Damato, A; Longo, L; Barbieri, F; Bertolini, F; Stefani, A; Migaldi, M; Gnetti, L; Camisa, R; Bordi, P; Buti, S; Rossi, G (2017) *Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)* LUNG CANCER 104():24-30 **IF<sub>2017</sub>=4.486** [Article]

Zagonel, V; Franciosi, V; Brunello, A; Biasco, G; Brogna, C; Cattaneo, D; Cavanna, L; Corsi, D; Farina, G; Fioretto, L; Gamucci, T; Lanzetta, G; Magarotto, R; Maltoni, M; Marchetti, P; Massa, E; Mastromauro, C; Melotti, B; Meriggi, F; Nacci, A; Pavese, I; Piva, E; Quirino, M; Roselli, M; Sacco, C; Tonini, G; Trentin, L; Ucci, G; Labianca, R; Gori, S; Pinto, C; Cascinu, S (2017) *Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (Simultaneous Care)* TUMORI 103(1):9-14 **IF<sub>2017</sub>=1.304** [Review]